DarshanTalks Podcast
Welcome to DarshanTalks!
We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there!
Powered By The Kulkarni Law Firm - Helping regulators see your business the way you do.
We focus on life science issues involving medical affairs, marketing and advertising, and clinical research so that you can learn about the industry, enhance your business and grow your career.
DarshanTalks Podcast
The Messy Reality of AI Prescriptions
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
State governments are racing to innovate by allowing AI to renew and improve prescriptions—but are they walking into a federal trap? In this episode of KLF Deep Dive, Darshan Kulkarni breaks down the "Utah Sandbox" model and the three massive warning signs flashing for the life sciences industry. From misdiagnosis risks to the nightmare of liability ownership, we explore why "innovation" doesn't grant immunity from federal law or malpractice lawsuits. If you are a healthcare executive or legal professional, this is the regulatory reality check you can't afford to miss.
www.kulkarnilawfirm.com
So why is the FDA nervous that states are letting AI prescribe drugs? It's because states are quietly testing AI systems that can improve or renew prescriptions with minimal doctor involvement. And that raises real regulatory risk. I'm a pharmacist, I'm a lawyer, so I look at this from both sides, the medicine and the law, and both are flashing warning signs. First, there's the misdiagnosis risk. Studies already show that AI is guiding real health decisions and sometimes getting it wrong. When AI misses symptoms, care gets delayed. A state sandbox does not magically fix bad clinical logic. Second, liability confusion. If an AI refills a drug like you're seeing in Utah, a patient may be harmed. Who owns that decision? The software company? The pharmacy? The supervising clinician? States can waive rules, but they can't waive lawsuits.
SPEAKER_00Enjoying our content? We'd love to hear more. Please like, comment, share, and find more.
DarshanThird, federal oversight still applies. The FTA regulates drugs, devices, and software. And this is tied directly to patient safety. States cannot override federal law just because the innovation sounds exciting. And this is exactly the kind of issue we break down on KLF Deep Diet. If you want clear, practical takes on where healthcare regulation is heading, subscribe. Call, click, click or email.
